ZYVERSA THERAPEUTICS, INC. Operating Lease, Payments
ZYVERSA THERAPEUTICS, INC. (ZVSA) reported Operating Lease, Payments of $8.66 thousand for the 12-month period ending 2024-12-31, per its 10-K filed 2025-03-27.
Financial Statements › Cash Flow › Other Cash Flow Items
us-gaap:OperatingLeasePayments · last filed 2025-03-27
- ZYVERSA THERAPEUTICS, INC. operating lease, payments for the quarter ending 2024-12-31 was $0.00, a 100.00% decline year-over-year.
- ZYVERSA THERAPEUTICS, INC. operating lease, payments for the quarter ending 2024-09-30 was $0.00, a 100.00% decline year-over-year.
- ZYVERSA THERAPEUTICS, INC. operating lease, payments for the quarter ending 2024-06-30 was $0.00, a 100.00% decline year-over-year.
- ZYVERSA THERAPEUTICS, INC. operating lease, payments for the quarter ending 2024-03-31 was $8.66K, a 64.30% decline year-over-year.
- ZYVERSA THERAPEUTICS, INC. operating lease, payments for fiscal 2024 was $8.66K, a 91.35% decline from fiscal 2023.
- ZYVERSA THERAPEUTICS, INC. operating lease, payments for fiscal 2023 was $100.10K, a 1991.50% increase from fiscal 2022.
- ZYVERSA THERAPEUTICS, INC. operating lease, payments for fiscal 2022 was $4.79K.
| Period end | Operating Lease, Payments 1 month | Operating Lease, Payments 3 month | Operating Lease, Payments 3 month as first filed | Operating Lease, Payments 6 month | Operating Lease, Payments 9 month | Operating Lease, Payments 11 month | Operating Lease, Payments 12 month |
|---|---|---|---|---|---|---|---|
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-27 | $0.00 derived: sum of 2 quarters · filed 2025-03-27 | $0.00 derived: sum of 3 quarters · filed 2025-03-27 | $8.66K 10-K · filed 2025-03-27 | |||
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | $0.00 derived: sum of 2 quarters · filed 2024-11-14 | $8.66K 10-Q · filed 2024-11-14 | $34.35K derived: sum of 4 quarters · filed 2025-03-27 | |||
| 2024-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-09 | $8.66K 10-Q · filed 2024-08-09 | $34.35K derived: sum of 3 quarters · filed 2025-03-27 | $59.63K derived: sum of 4 quarters · filed 2025-03-27 | |||
| 2024-03-31 | $8.66K 10-Q · filed 2024-05-15 | $34.35K derived: sum of 2 quarters · filed 2025-03-27 | $59.63K derived: sum of 3 quarters · filed 2025-03-27 | $84.51K derived: sum of 4 quarters · filed 2025-03-27 | |||
| 2023-12-31 | $25.69K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-27 | $50.97K derived: sum of 2 quarters · filed 2025-03-27 | $75.85K derived: sum of 3 quarters · filed 2025-03-27 | $100.10K 10-K · filed 2025-03-27 | |||
| 2023-09-30 | $25.27K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | $50.16K derived: sum of 2 quarters · filed 2024-11-14 | $74.41K 10-Q · filed 2024-11-14 | ||||
| 2023-06-30 | $24.88K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-09 | $49.13K 10-Q · filed 2024-08-09 | |||||
| 2023-03-31 | $24.25K 10-Q · filed 2024-05-15 | $24.25K 10-Q · filed 2023-05-12 | |||||
| 2022-12-31 | $4.79K 10-K · filed 2024-03-25 | $4.79K 10-K · filed 2023-03-31 | |||||
| 2022-12-12 | $86.10K 10-K · filed 2024-03-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B | |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| ORAGENICS INC (OGEN) | United States | $0.002B | |
| Petros Pharmaceuticals, Inc. (PTPI) | United States | $0.003B | |
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| Nexentis Technologies Inc. (NXTS) | $0.002B | ||
| Decoy Therapeutics Inc. (DCOY) | United States | $0.002B | -0.27 |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |